OTLK
Outlook Therapeutics, Inc.NASDAQHealthcare$0.22+4.29%ClosedMarket Cap: $9.0M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
-0.31
P/S
40.15
EV/EBITDA
-0.60
DCF Value
$2.32
FCF Yield
-181019981.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
-588.7%
Operating Margin
-28675.8%
Net Margin
-50045.1%
ROE
293.1%
ROA
-564.0%
ROIC
-983.5%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 2026 | $-1.2M | 102.5% | $-13.5M | $-23.1M | $-0.38 | — |
| Q4 2025 | $-91.8K | 1098.5% | $-17.3M | $-13.3M | $-0.52 | — |
| FY 2025 | $1.4M | 46.5% | $-67.1M | $-62.4M | $-1.79 | — |
| Q3 2025 | $1.5M | 70.8% | $-15.7M | $-20.2M | $-0.55 | — |
| Q2 2025 | $0.00 | -Infinity% | $-12.4M | $-46.4M | $-1.50 | — |
| Q1 2025 | $0.00 | -Infinity% | $-21.6M | $17.4M | $0.72 | — |
| Q4 2024 | $170.1K | 50.0% | $-22.9M | $5.7M | $0.31 | — |
| FY 2024 | $0.00 | -Infinity% | $-71.7M | $-75.4M | $-4.06 | — |
| Q3 2024 | $0.00 | -Infinity% | $-19.6M | $44.4M | $-0.89 | — |
| Q2 2024 | $0.00 | -Infinity% | $-18.9M | $-114.3M | $-8.01 | — |
| Q1 2024 | $0.00 | -Infinity% | $-10.3M | $-11.2M | $-0.86 | — |
| Q4 2023 | $0.00 | -Infinity% | $-12.5M | $-13.0M | $-1.00 | — |